|Bid||17.69 x 3200|
|Ask||17.70 x 1800|
|Day's Range||17.17 - 17.79|
|52 Week Range||15.50 - 23.52|
|Beta (5Y Monthly)||0.78|
|PE Ratio (TTM)||34.82|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.
The stock market continues to be under pressure due to geopolitical tensions and various economic problems. For instance, cancer-focused biotech company Exelixis (NASDAQ: EXEL) has run circles around the broader market year to date. Can Exelixis continue beating the market from here on out?
The stock market is highly volatile now. Robotic-assisted surgery is the future of surgery, and Intuitive Surgical (NASDAQ: ISRG) is already dominating the space. Biotech company Exelixis (NASDAQ: EXEL) and internet retail company Etsy (NASDAQ: ETSY) also have remarkable growth prospects that could bring in some exciting long-term returns.